1|0|Public
40|$|Two {{randomised}} double blind, placebo controlled {{trials have}} been carried out to assess the effectiveness of <b>nonathymulin,</b> a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). <b>Nonathymulin</b> 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56 % v 17 % in the placebo group) (p less than 0. 02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to <b>nonathymulin,</b> and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay...|$|E

